LSI Segment Divestment
Full-Year 2020 LSI Performance Overview
Overall margin improvement as cost increases were offset by higher demand
Specialty Ingredients (LSI)¹ delivered a strong performance, with 3.4% CER sales
growth alongside an improved CORE EBITDA margin, reported at 20.3%2
Impacts of COVID-19 were largely managed across the business portfolio
High demand for disinfection solutions from Microbial Control Solutions division to
support in managing the COVID-19 pandemic
Lonz
Carve-out finalized, portfolio showed resilience in top and bottom line, efficient
strategy and market-oriented organization in place.
1 Speciality Ingredients Business (excluding Corporate/carve-out and divestiture costs directly attributable to LSI)
2 CORE EBITDA margin at a constant exchange rate (CER)
CORE definition: See appendix
29View entire presentation